MindMed Collaborators Announce Positive Topline Data from Phase 2 Trial Evaluating LSD in Anxiety Disorders
MindMed’s collaborators at University Hospital Basel studied the effect of two high doses of LSD (200μg) on patients with anxiety disorders.
They found that 65% of subjects had significant reductions in anxiety scores for 16 weeks after the treatments.
Like many other studies have found, mystical experiences were significantly correlated with long-term therapeutic benefits.